Glenmark’s Ryaltris Set To Hit Canadian Market
Following A Spate Of International Authorizations For The Allergy Drug
Health Canada approves Ryaltris for allergic rhinitis, opening up yet another major market for Glenmark’s branded specialty medicine. Bausch Health will sell the drug in Canada.
